title: [D-dimer, thrombin-antithrombin III-complex (TAT) and prothrombin fragment 1+2 (PTF). Parameters for monitoring therapy with low molecular-weight heparin in coagulation disorders].
abstract: Two groups of 15 patients each with disseminated intravascular coagulation in association with septic disease were treated with low-molecular-weight heparin (lmw-heparin) in different dosages (group I: 1.5-5 IE/kg body weight (BW) per hour; group II: 8-15 IE/kg BW). We studied the levels of D-dimer, thrombin-antithrombin III complex (TAT), prothrombin fragments 1 and 2 (PTF), and global tests of coagulation like prothrombin time (PT), activated partial thromboplastin time (PTT), thrombin time (TT) and platelet count, plasminogen activation (PA) and fibrinogen concentration to estimate the success of heparin therapy in the two groups. TT and fibrinogen concentration were not suitable to follow the course of the coagulation disorder, PT, PTT, platelet count progressively PA, D-dimer, TAT, and PTF normalised progressively after heparinisation. However, only the last three parameters were sensitive enough to show different effects of variable dosages of lmw-heparin. D-dimer, TAT, and PTF levels declined in proportion with heparin concentrations, and thus appear to be the most useful parameters for monitoring the therapeutic effect of heparin in septic coagulopathies.
authors.affiliation: Universitäts-Frauenklinik Mainz.
authors.forename: M
authors.initials: M
authors.lastname: Hofmann
authors.forename: A
authors.initials: A
authors.lastname: Rest
authors.forename: G
authors.initials: G
authors.lastname: Hafner
authors.forename: B
authors.initials: B
authors.lastname: Tanner
authors.forename: P
authors.initials: P
authors.lastname: Brockerhoff
authors.forename: L S
authors.initials: LS
authors.lastname: Weilemann
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D000990:Antithrombin III / Q000032:analysis*; D015415:Biomarkers / Q000097:blood; D001778:Blood Coagulation Disorders / Q000097:blood / Q000188:drug therapy*; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000150:complications / Q000188:drug therapy; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010446:Peptide Fragments / Q000032:analysis*; D010447:Peptide Hydrolases / Q000032:analysis*; D011516:Prothrombin / Q000032:analysis*; D011517:Prothrombin Time; D018805:Sepsis / Q000150:complications
chemical_list: D000925:Anticoagulants; D015415:Biomarkers; D006495:Heparin, Low-Molecular-Weight; D010446:Peptide Fragments; C046193:antithrombin III-protease complex; C045879:prothrombin fragment 1.2; D000990:Antithrombin III; D011516:Prothrombin; D005340:Fibrinogen; D010447:Peptide Hydrolases